CIPLA
|
|
| BOM : 500087 NSE : CIPLA | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Nov 19,2024 |
|
Price(EOD): ₹ 1,471.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 118,826.23 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CIPLA | -3.5% | -5.2% | 18% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -7.1% | 48% |
| DR REDDYS LABORATORIES | -3.9% | -10.1% | 10.1% |
| ZYDUS LIFESCIENCES | -0.3% | -7.3% | 52.2% |
| DIVIS LABORATORIES | 1.5% | -2.1% | 63% |
| MANKIND PHARMA | -2.3% | -3% | 39.6% |
| TORRENT PHARMACEUTICALS | -1.8% | -10.2% | 51.3% |
| LUPIN | -2.4% | -6.4% | 73.9% |
| AUROBINDO PHARMA | -1.5% | -15.2% | 27.9% |
FUNDAMENTAL ANALYSIS OF CIPLA
[ Q(TTM): Sep2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF CIPLA
[As on : Nov 19,2024
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
26.49
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 4,485.22 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 4.46
P/B Calculated based on Book Value of Rs 26,619.90 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.48
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 26,512.00 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
55% 29% 36% |
SHARE PRICE MOMENTUM OF CIPLA
CIPLA vs SENSEX
DEBT OF CIPLA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0.01 0.02 0.04 0.02 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF CIPLA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Dec2023 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF CIPLA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
5.33% 9.9% 11.03% 11.03% |
5.58% 8.76% 12.22% 13% |
| QtrlyTrend |
8 | |
| Latest Qtr: Sep2024 | ||
| Quarterly Result Analysis → | ||
CIPLA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE CARBONEX | 1.5% | 1.4% | 34.5% |
| S&P BSE GREENEX | 0.9% | 1.7% | 52.5% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE 100 ESG INDEX | -2.2% | -5% | 22.2% |
| S&P BSE HEALTHCARE | -2.5% | -4% | 46.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY GROWTH SECTOR 15 | 1.2% | 11.6% | 9.1% |
| NIFTY LARGE MIDCAP 250 | -2.5% | -6.1% | 28.8% |
| NIFTY 200 | -2.5% | -5.6% | 26.4% |
| NIFTY 100 | -2.6% | -5.4% | 25.2% |
| NIFTY PHARMA | -2.6% | -6.4% | 40.5% |
You may also like the below Video Courses
FAQ about CIPLA
Is CIPLA good for long term investment?
As on Nov 19,2024, the Fundamentals of CIPLA look Strong and hence it may be good for long term investment! See Financial Performance of CIPLA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is CIPLA UnderValued or OverValued?
As on Nov 19,2024, CIPLA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of CIPLA ?
As on Nov 19,2024, the Intrinsic Value of CIPLA is Rs. 1,081.07 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 951.52
Fair Value [Median EV / Sales Model] : Rs. 1,142.47
Fair Value [Median Price / Sales Model] : Rs. 1,081.07
Estimated Median Fair Value of CIPLA : Rs. 1,081.07
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
